HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment

Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described a high instability of HER2-low-positive expression from primary breast cancer (BC) to relapse. Previous studies reporting discordance in HER2 status between baseline biopsy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Miglietta, Federica, Griguolo, Gaia, Bottosso, Michele, Giarratano, Tommaso, Lo Mele, Marcello, Fassan, Matteo, Cacciatore, Matilde, Genovesi, Elisa, De Bartolo, Debora, Vernaci, Grazia, Amato, Ottavia, Porra, Francesca, Conte, PierFranco, Guarneri, Valentina, Dieci, Maria Vittoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122970/
https://www.ncbi.nlm.nih.gov/pubmed/35595761
http://dx.doi.org/10.1038/s41523-022-00434-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122970/
https://www.ncbi.nlm.nih.gov/pubmed/35595761
http://dx.doi.org/10.1038/s41523-022-00434-w

Ejemplares similares